DRIVe EZ-BAA - Special Instructions 017.pdf

Office of Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation & Ventures (DRIVe)

Special Instructions 017 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002

The purpose of these Special Instructions is the following:

1) Pause “Area of Interest (AOI) #6: Beyond the Needle” until further notice.

I. INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under these Special Instructions 017, BARDA is pausing AOI #6 as part of its EZ-BAA (BAA-20- 100-SOL-0002) until further notice.

B. Eligible Respondents & Scope Parameters:

These Special Instructions are open to all responsible sources as described in the EZ-BAA.

Abstract submissions that do not conform to the requirements outlined in the EZ-BAA may be considered non-responsive and will not be reviewed. To clarify, an entity must have an active registration with https://sam.gov at the time of submission to be reviewed. If not, submissions will not be reviewed and will be rejected. Please do not attempt to submit an abstract if your registration is not active in https://sam.gov.

IMPORTANT NOTE: Interested vendors are strongly encouraged to submit a request to schedule a market research call. This request should include the project title, key project staff, and a brief description of the proposed project. Please submit the requests to the following:

AOI #2: Infection Severity and Solving Sepsis (solvingsepsis@hhs.gov) AOI #5: ReDirect (chemrepo@hhs.gov) AOI #8: Bringing Laboratory Testing to the Home (homediagnostics@hhs.gov) AOI #9: Digital Health Tools for Pandemic Preparedness (digitalhealth@hhs.gov) AOI #10: NGS-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens (NGS@hhs.gov) AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 (COVID19_homeDx@hhs.gov) AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection (COVID19_homeDx@hhs.gov) AOI #12: Mitigating Long-term Effects (MILE) of Respiratory Distress (HostTx@hhs.gov)

AOI #2 will be open for abstract submissions through 5:00 PM ET on 15 January 2022, unless otherwise extended.

AOI #5 will be open for abstract submissions through 5:00 PM ET on 31 March 2022, unless otherwise extended.

AOIs #8, and #9 will be open for abstract submissions through 5:00 PM ET on 03 February 2023, unless otherwise extended.

AOI #10 will be open for abstract submissions through 5:00 PM ET on 30 November 2021, unless otherwise extended.

AOIs #11a and #11b will be open for abstract submissions through 5:00 PM ET on 15 January 2022, unless otherwise extended.

https://sam.gov/ https://sam.gov/ mailto:solvingsepsis@hhs.gov mailto:chemrepo@hhs.gov mailto:homediagnostics@hhs.gov mailto:digitalhealth@hhs.gov mailto:NGS@hhs.gov mailto:COVID19_homeDx@hhs.gov mailto:COVID19_homeDx@hhs.gov mailto:HostTx@hhs.gov

AOI #12 will be open for abstract submissions through 5:00 PM ET on 30 April 2022, unless otherwise extended.

C. Number of Awards:

Multiple awards are anticipated and are dependent upon the program priorities, scientific/technical merit of submissions, how well submissions fit within the goals of the AOI, and the availability of funding. The program funding is subject to change based on the Government’s discretion.

Additionally, award(s) expected to be made under these Special Instructions will be less than $750,000 in total Government funding. Funding is limited, so we encourage any interested vendors to reach out to the respective program as soon as possible before submitting an abstract.

D. Special Instructions Application Process:

These Special Instructions will follow the same submission process and review procedures as those established under the EZ-BAA. For complete details, please read the EZ-BAA solicitation in its entirety. DRIVe takes the protection of Respondent information very seriously to ensure that information is safeguarded in full compliance with all applicable regulations and law.

IMPORTANT NOTE: Awarded partners under each of these AOIs will be required to share any collected de-identified data in an effort to advance the field and knowledge. Interested partners are encouraged to commercialize their technology and algorithms but data collected through the use of Government funding will be made available through full Government purpose rights.